Phase 1 Clinical Trial of AAV-AQP1

We are currently conducting a Phase 1 dose escalation clinical trial in patients with grade 2 or 3 radiation-induced xerostomia (RIX) who remain cancer free for at least five years (or two years if HPV+) after receiving radiation treatment. The aim of the trial is to determine the safety of inserting the gene for the human aquaporin water channel (hAQP1) locally into the salivary glands of RIX patients and to measure changes in salivary flow resulting from the introduction of this channel.


The FDA granted orphan drug designation for AAV-AQP1 to treat symptoms of grade 2 and grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.


View clinical trial information here